168 related articles for article (PubMed ID: 30592973)
1. Can the Toll-like receptors 4 expression in peripheral blood mononuclear cells help assess the effectiveness of immunosuppression and the chance of a future good renal transplant function?
Zmonarski SC; Madziarska K; Golebiowski T; Banasik M; Mazanowska O; Madziarski M; Krajewska M
Transpl Immunol; 2019 Apr; 53():43-50. PubMed ID: 30592973
[TBL] [Abstract][Full Text] [Related]
2. Expression of PBMC TLR4 in Renal Graft Recipients Who Experienced Delayed Graft Function Reflects Dynamic Balance Between Blood and Tissue Compartments and Helps Select a Problematic Patient.
Zmonarski S; Madziarska K; Banasik M; Mazanowska O; Magott-Procelewska M; Hap K; Krajewska M
Transplant Proc; 2018; 50(6):1744-1749. PubMed ID: 30056893
[TBL] [Abstract][Full Text] [Related]
3. Lowering of Messenger Ribonucleic Acid Toll-Like Receptors 2-4,9 in Peripheral Blood Mononuclear Cells in Kidney Allograft Recipients, Relationships With Immunosuppressive Treatment, and Delayed Graft Function Occurrence.
Zmonarski SC; Kościelska-Kasprzak K; Banasik M; Myszka M; Żabińska M; Madziarska K; Mazanowska O; Krajewska M; Boratyńska M; Klinger M
Transplant Proc; 2016 Jun; 48(5):1519-25. PubMed ID: 27496439
[TBL] [Abstract][Full Text] [Related]
4. Toll-like 4 receptor (TLR4) expression on peripheral blood mononuclear cells in renal transplant recipients with pre-transplant chronic interstitial nephritis indicates patients at risk of graft deterioration.
Zmonarski SC; Banasik M; Golebiowski T; Madziarska K; Mazanowska O; Myszka M; Zmonarska J; Letachowicz K; Dawiskiba T; Krajewska M
Transpl Immunol; 2020 Oct; 62():101319. PubMed ID: 32693120
[TBL] [Abstract][Full Text] [Related]
5. Toll-Like 4 Receptor Expression on Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Can Help to Indicate the Risk of Graft Deterioration in Patients Who Experienced an Episode of Symptomatic Cytomegalovirus Infection.
Zmonarski SC; Banasik M; Gołębiowski T; Letachowicz K; Madziarska K; Żabińska M; Zmonarska J; Mazanowska O; Krajewska M
Transplant Proc; 2020 Oct; 52(8):2394-2402. PubMed ID: 32444127
[TBL] [Abstract][Full Text] [Related]
6. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.
Neu AM; Ho PL; Fine RN; Furth SL; Fivush BA
Pediatr Transplant; 2003 Jun; 7(3):217-22. PubMed ID: 12756047
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
[TBL] [Abstract][Full Text] [Related]
10. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
Bunnapradist S; Daswani A; Takemoto SK
Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver transplantation.
Howell J; Sawhney R; Testro A; Skinner N; Gow P; Angus P; Ratnam D; Visvanathan K
Liver Transpl; 2013 Oct; 19(10):1099-107. PubMed ID: 23894100
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
[TBL] [Abstract][Full Text] [Related]
14. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
16. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
van Gelder T; Silva HT; de Fijter H; Budde K; Kuypers D; Mamelok RD; Armstrong VW; Oellerich M
Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657
[TBL] [Abstract][Full Text] [Related]
17. Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients.
Michielsen LA; van Zuilen AD; Verhaar MC; Wisse BW; Kamburova EG; Joosten I; Allebes WA; van der Meer A; Baas MC; Spierings E; Hack CE; van Reekum FE; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JF; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; Hilbrands LB
Nephrol Dial Transplant; 2019 Aug; 34(8):1417-1422. PubMed ID: 30561730
[TBL] [Abstract][Full Text] [Related]
18. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
Wojciechowski D; Chandran S; Vincenti F
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of immunosuppressive treatment on homocystein levels in patients after kidney transplantation during a 2 year observation period].
Aksamit D; Janda K; Kuźniewski M; Krzanowski M; Ignacak E; Betkowska-Prokop A; Chowaniec E; Sułowicz W
Przegl Lek; 2012; 69(11):1175-9. PubMed ID: 23646442
[TBL] [Abstract][Full Text] [Related]
20. Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications.
El-Agroudy AE; El-Dahshan K; Mahmoud K; El-Baz M; Shokeir AA; Ghoneim MA
Ann Transplant; 2008; 13(4):46-54. PubMed ID: 19034223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
